Cosmos Health Unveils Patented Cur18 Supplement with 39x Higher Bioavailability for Q2 US Launch
COSM sits 43% above its 52-week low of $0.28 on elevated volume (2.8× avg).
Summary
Cosmos Health announced the planned Q2 2026 U.S. launch of Cur18, a patented curcumin supplement designed to support joint health, claiming significantly enhanced bioavailability. This launch continues the company's U.S. expansion in the nutraceutical market, following recent announcements for Liv18 and NOOR collagen products. While the introduction of a new, clinically studied product with strong bioavailability claims is positive for the company's portfolio, it comes shortly after Cosmos Health reported a "going concern" warning in its recent 10-K filing. Traders will monitor the sales performance of Cur18 and other new products, alongside the company's efforts to address its financial challenges.
At the time of this announcement, COSM was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.3M. The 52-week trading range was $0.28 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Access Newswire.